Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Antimicrob Chemother. 2005 Mar;55(3):283-8. Epub 2005 Feb 10.

Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.

Author information

  • 1Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, MA 02421, USA. Judith.steenbergen@cubist.com

Abstract

Infections caused by drug-resistant pathogens are on the rise. Daptomycin, a cyclic lipopeptide with activity against most Gram-positive pathogens, including vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus, is a newly US-FDA approved antimicrobial for complicated skin and skin structure infections (cSSSI). Daptomycin has a unique mechanism of action that results in destruction of the membrane potential. The rapid bactericidal activity of daptomycin makes it an attractive antibiotic for serious Gram-positive infections.

PMID:
15705644
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk